Thu, Jan 29, 3:20 PM, Zacks
Alexion Misses on Q4 Earnings, 2015 Outlook Disappoints - Analyst Blog
Alexion Pharmaceuticals (ALXN) fourth-quarter 2014 earnings (including stock-based compensation expense) of $1.15 per share.
Thu, Jan 29, 3:19 PM, Zacks
Salix Financial Results Need Correcting: Audit Committee - Analyst Blog
The audit committee of the board of directors of Salix Pharmaceuticals (SLXP) announced that the company's consolidated financials require corrections.